iGreen Think Tank Releases Independent ESG Research, Highlighting China Overseas Land & Investment Ltd.'s Verified Low-Carbon and Governance Performance
SHENZHEN, China, Dec. 16, 2025 /PRNewswire/ -- iGreen Think Tank, an independent research institution specializing in sustainable development and ESG evaluation, has released its latest independent ESG research and quantitative assessment at the 3rd...
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
SAN FRANCISCO, Dec. 16, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea...
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug...
Global Spotlight｜POGMENT Biomimetic Collagen "Stable Triple Helix" Breakthrough Stuns the World--Extraordinary and Breathtaking
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- Recently, LivingPhoenix Regenerative Technologies has captured widespread attention with its world-first "Stable Triple-Helix Biomimetic Collagen" technology, making consecutive appearances at 12...
Final Report Meeting on the Achievements of the Cheongju Craft Biennale 2025: Record-Breaking Economic Impact
- The achievement analysis report meeting took place on Wednesday, December 10, at 4:00 pm in the fourth-floor conference room of the Main Building, Culture Factory. - Visitor satisfaction reached 90.3%, and the economic ripple effect increased to...
12TH ANNUAL WINTERNATIONAL EMBASSY SHOWCASE DRAWS 8,000 GUESTS
70 Embassies Unite to Celebrate Global Culture and Traditions at the Ronald Reagan Building and International Trade Center in Washington, DC WASHINGTON, Dec. 12, 2025 /PRNewswire/ -- On Tuesday, December 9, 2025, the 12th Annual Embassy Showcase,...
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc....
Yiren Digital Wins "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards
BEIJING, Dec. 11, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital" or the "Company"), a leading Fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast...
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody)...
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter...